



*JPM*

PATENT  
Attorney Docket No. 056291-5190

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Initial Application of: **Laurent F. A. HENNEQUIN et al.** ) Confirmation No. 5077  
)  
Application No.: **10/520,266** ✓ ) Group Art Unit: **1614**  
)  
Filed: **January 6, 2005** ) Examiner: *Unassigned*  
)  
For: **QUINZOLINE DERIVATIVES FOR USE IN** )  
**THE TREATMENT OF CANCER** )

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

**Citation of Related U.S. Patent Applications**

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

<b>Inventor</b>	<b>U.S. Serial No. Filing Date</b>	<b>U.S. Patent No. Issue Date</b>	<b>PCT Publication No. PCT Publication Date</b>
Andrew Austen Mortlock	10/088,854		WO 01/21594 March 29, 2001
Laurent Francois Andre Hennequin et al.	10/275,382 November 5, 2002		WO 01/94341 December 13, 2001
Laurent Francois Andre Hennequin et al.	10/344,678 February 14, 2003		WO 02/016352 February 28, 2002
Patrick Ple	10/475,016 October 16, 2003		WO 02/085895 October 31, 2002
Laurent Francois Andre Hennequin	10/483,782 August 11, 2004		WO 03/008409 January 30, 2003

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith.

**PLEASE DO NOT PRINT** the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

#### **Citation of Documents**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.


Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,  
Morgan Lewis & Bockius LLP



Date: October 19, 2005  
Morgan Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By:

Registration No. 25 323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

